Findit, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 13, 2022 at 12:55 am IST
Share
Findit, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 0.014258 million compared to USD 0.072801 million a year ago. Net loss was USD 0.033263 million compared to USD 0.010874 million a year ago.
For the six months, revenue was USD 0.021962 million compared to USD 0.149115 million a year ago. Net loss was USD 0.070582 million compared to USD 0.006807 million a year ago.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.